Tuesday, November 25, 2025 4:42:45 PM
Guessing what kind of gyrations up and down the price action does in these next few weeks will be very tricky in my view. This morning we saw a 70 cent jump at the opening, sold back down 50 cents, and then settled into the middle zone around 3.40/3.30 area for today. Resistance remains 3.70 area/ 3.50 area and “support “ tries again to develop around 3.25/3.15 , still very early and uncertain. What seems to me much more certain is that when the December decision happens, if it’s a rejection, price will likely nose dive probably to 2 dollars for starters. And spend weeks developing the grand Bottom and getting off the floor. But it will recover when the next good news happens.
If the December decision is good, then price ought to surge at least right back to 10 dollars for starters, and the trading waves might look like the have in recent years, 10 to 7, to 14, to 10, and up and down like before, and if the complexity of the EMA approval process involves partial acceptance, conditional approval, etc, that gives the short attackers the opportunity to spin a negative hit , then it ought to cause big gyrations in the wave patterns, and we’ll see these rallies to 12 dollars get tumbled down to 5, and rally back to 10 and down again to 5, and the roller coaster ride continues until the news cycle changes this uncertainty.
Right now , I might guess that any climb back toward 4 dollars will have a struggle getting there and staying there, would probably be hammered back to retest 3 dollars again. And if we do see a breakout above 4 dollars, it will go only as high as the next short attack sets up, just before the December decision and then the hammer slams down. At the moment on my chart picture, I think the 4.75/5.00 area would be the highest I can imagine for this current chart and news cycle dilemma, heading towards the December decision.
If the December decision is good, then price ought to surge at least right back to 10 dollars for starters, and the trading waves might look like the have in recent years, 10 to 7, to 14, to 10, and up and down like before, and if the complexity of the EMA approval process involves partial acceptance, conditional approval, etc, that gives the short attackers the opportunity to spin a negative hit , then it ought to cause big gyrations in the wave patterns, and we’ll see these rallies to 12 dollars get tumbled down to 5, and rally back to 10 and down again to 5, and the roller coaster ride continues until the news cycle changes this uncertainty.
Right now , I might guess that any climb back toward 4 dollars will have a struggle getting there and staying there, would probably be hammered back to retest 3 dollars again. And if we do see a breakout above 4 dollars, it will go only as high as the next short attack sets up, just before the December decision and then the hammer slams down. At the moment on my chart picture, I think the 4.75/5.00 area would be the highest I can imagine for this current chart and news cycle dilemma, heading towards the December decision.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
